Pay in 4 interest-free payments of $6.87 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
A Phase III trial is scheduled to begin in the second half of 2025, positioning denifanstat to potentially become the first approved FASN inhibitor for NASH
Researchers seeking access to retatrutide for any clinical context, including individual treatment, should contact Eli Lilly directly or enrol in an authorized clinical trial
For decades, patients with type 1 diabetes have depended on daily insulin injections to survive but this breakthrough could end that cycle
Bioscience 39: 230-237
/assets/images/provider/photos/2813769.png)
US$ 27.36
US$ 24.27
US$ 25.22
US$ 25.22
